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| INTRODUCTION
Current treatment guidelines recommend a glycated haemoglobin A1c (HbA1c) level of less than 7.0% (<53 mmol/mol) as the goal for most individuals with type 2 diabetes mellitus (T2DM). 1, 2 The American Diabetes Association (ADA) 2 guidelines recommend a stepwise approach to therapies if glycaemic targets are not achieved, with basal insulin considered as second-line or later therapy, with the exception of very poor glycaemic control (HbA1c >9.0%; >75 mmol/mol). Similarly, the recently updated ADA/European Association for the Study of Diabetes (EASD) consensus report recommends a stepwise approach to therapies in individuals with T2DM who are not at glycaemic target. However, with the exception of patients with HbA1c >11.0% (97 mmol/ mol), addition of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) as first injectable is recommended, with addition of basal insulin as second injectable. 3 Currently, 24%-54% of individuals with T2DM worldwide prescribed supplementary basal insulin do not achieve their therapeutic targets. 4 Clinical inertia, defined as failure to adequately intensify treatment regimens sufficiently early, is an important contributing factor. 5 Identifying biomedical predictors of treatment success may assist clinicians in the selection of therapeutic interventions. Therefore, a better understanding of the relationship between baseline characteristics and glycaemic outcomes may help to prevent unnecessary delay in optimizing the use of basal insulin therapy. Previous studies have investigated the relevance of baseline characteristics to determine effective outcomes in individuals with T2DM who are initiating insulin therapy. 4, [6] [7] [8] [9] Those characteristics that have been shown to be associated with an inadequate glycaemic response, that is, not achieving HbA1c less than 7.0% (<53 mmol/mol), include the number of oral anti-hyperglycaemic drugs (OADs) prescribed at baseline, in addition to HbA1c, fasting plasma glucose (FPG) levels, body mass index (BMI), diabetes duration and sex. 4, [6] [7] [8] [9] The goal of this pooled participant-level analysis of 16 randomized controlled clinical trials (RCTs) was to further investigate, in a larger cohort exposed to the same basal insulin treatment, which baseline and post-baseline characteristics better predict the glycaemic response and achievement of HbA1c less than 7.0% at 24 weeks with the introduction and titration of basal insulin glargine 100 units (U)/mL (Gla-100), administered once daily at bedtime in combination with existing OADs.
| MATERIALS AND METHODS

| Study and participant selection
Participant-level data were collected and pooled for analysis from RCTs of up to 24 weeks, conducted by Sanofi, the manufacturer of Gla-100 (Lantus, Paris, France) between 2000 and 2015. To fulfil the inclusion criteria for this analysis, all trials were required to enrol insulin-naïve individuals whose T2DM was inadequately controlled (HbA1c >7.0%; >53 mmol/mol) while using OADs, with at least one study arm commencing once-daily Gla-100, and no other basal insulin, and using a titration algorithm, predominantly a once-weekly dose adjustment of 2-8 U/d, based on the patient's self-measured plasma glucose (SMPG) to achieve an FPG of ≤5.6 mmol/L (≤100 mg/dL). Sixteen studies that met the inclusion criteria were identified and have been described elsewhere. 9 All study participants (N = 3415) for whom data were analysed were mainly receiving one (metformin or sulfonylurea) or two OADs (metformin with a sulfonylurea); a few participants received other OADs alone or in combination (eg, gliptin, thiazolidinedione or glinide) with Gla-100 ( Figure S1 ).
| Outcomes
All clinical outcomes were assessed over the 24-week study period according to response, with participants stratified by HbA1c level at 24 weeks into "good responders" reaching HbA1c less than 7.0% (<53 mmol/mol) and "poor responders" with HbA1c ≥7.0% (≥53 mmol/mol). Outcomes in the poor responder group were further divided into "suboptimal" (7.0%-8.0%; 53-64 mmol/mol) and "minimal" (>8.0%; >64 mmol/mol) responder subgroups. Hypoglycaemia was defined as a confirmed plasma glucose (PG) level of <3.9 mmol/L (<70 mg/dL) or as severe hypoglycaemia requiring third-party assistance.
Baseline characteristics and treatment-emergent events within the two responder groups were analysed primarily to identify factors that predicted achievement of an HbA1c target of <7.0% (<53 mmol/mol) at 24 weeks. Glycaemic outcomes per responder group were also subanalysed according to the frequency of hypoglycaemia events (ie, 0, 1-3, and ≥ 4 events) during the 24-week study. Average 2-hour post-prandial SMPG (2-h SMPG) was derived from the mean of the 2-hour post-breakfast, lunch and evening meal, both before baseline and at the Week 24 visit. (Table S2) 
| Statistical analysis
. A Hosmer and Lemeshow Goodness-of-Fit Test was
run on the logistic model to determine the significance between the observed and predicted probabilities, to confirm that there was no lackof-fit problem and that the linear assumption was therefore reasonable.
The final models consisted of the following covariates: sex, diabetes duration, baseline HbA1c, baseline FPG, baseline 2-h SMPG, baseline body weight, BMI, sulfonylurea use during the study, change in body weight and hypoglycaemia during the study.
| RESULTS
| Participant characteristics and demographic variables
A total of 7386 individuals participated in the 16 RCTs, of whom 3415 were initiated on once-daily Gla-100 and were thus eligible for inclusion in the analysis. Baseline clinical characteristics according to HbA1c responder groups are presented in Table 1 . At 24 weeks, 46.4% of participants achieved a good glycaemic response, as defined by an HbA1c level less than 7.0% (<53 mmol/mol) and 53.6% of participants had HbA1c levels ≥7.0% (53 mmol/mol). At 24 weeks, 43.6% and 27.7% of participants who achieved an HbA1c response <7.0% (53 mmol/mol) and ≥7.0% (53 mmol/mol), respectively, achieved an FPG target of ≤5.6 mmol/L (≤100 mg/dL) ( Table 2 ). Age and fasting C-peptide were similar across the two HbA1c responder groups, with a higher percentage of men than women in the good-responder group. Figure 1B and Figure S2B ). Interestingly, in both responder groups, an inverse relationship was observed between insulin dose and frequency of hypoglycaemia (Table 2) . Those participants who did not experience hypoglycaemia events had the highest insulin doses and dose increments at 24 weeks. The Gla-100 dose and dose increments at 24 weeks according to frequency of hypoglycaemia are shown in Figure S3 .
| Insulin dose and glycaemic control
HbA1c change within each of the responder groups differed only slightly among the different OADs used during the study period (Table S1 ). However, a smaller percentage of individuals reached HbA1c target at 24 weeks with concomitant sulfonylurea compared with the other OAD groups (32% vs 49%-57%).
FPG and 2-h SMPG levels at baseline and at 24 weeks were higher in the poor responder group ( Figure 1C , Figure S2C and Figure S4 ), although the reductions in these parameters during the course of the study were essentially similar in both responder groups: Table 2 ).
The 2-h SMPG levels at 24 weeks were higher in the poor-responder group compared with the good-responder group after each meal (breakfast, lunch and evening meal) ( Figure S4 ).
| Hypoglycaemia
The incidence and event rate of overall hypoglycaemia (PG <70 mg/dL; <3.9 mmol/L) or severe hypoglycaemia over 24 weeks was higher Figure 2 and Figure S5 ). Similarly, the proportion of participants who experienced one to three or four or more episodes of hypoglycaemia were fewer in the poor-responder group. Findings for nocturnal hypoglycaemia (PG <3.9 mmol/L) were similar to those for overall hypoglycaemia. The incidence of severe hypoglycaemia over 24 weeks was low at 2.0% in the responder groups.
In both responder groups, individuals who experienced the highest number of hypoglycaemia events had the lowest baseline fasting C-peptide levels and the lowest final Gla-100 dose (U/kg), a difference that was more evident in the poor-responder group (Figure 2 ).
| Body weight
Baseline and 24-week mean body weights were lower in the poorresponder group compared with the good-responder group (Tables 1   and 2 ). Mean change in body weight was lower in the good-responder group (+1.4 kg) than in the poor-responder group (+2.4 kg) ( Table 2) .
Within each responder group, participants with the lowest mean weight at baseline and at 24 weeks experienced a higher number of hypoglycaemia events. This was more notable in the poor-responder group, in which those experiencing four or more events had the lowest body weight at baseline and at 24 weeks, despite the greater weight gain during the study period ( Figure S6 ).
| Factors associated with attainment of HbA1c
<7.0% (<53 mmol/mol) at 24 weeks Univariable analysis identified potential explanatory factors among baseline demographic characteristics, as well as clinical variables, at 24 weeks and during the study period that were related to the attainment of an HbA1c target of <7.0% (<53 mmol/mol) ( Table 3) .
The relationship between baseline HbA1c values and the probability of reaching an end-of-trial target HbA1c of <7.0% (<53 mmol/mol) is illustrated in Figure 1D , corresponding to an OR of 0.53 (95% confidence interval [CI], 0.50-0.58) per 1%-unit (10.9 mmol/mol) ( Table 3 ). Female sex, known duration of diabetes, sulfonylurea use, hypoglycaemia incidence during the study and change in body weight were all negatively associated with the probability of achieving an HbA1c of <7.0% (<53 mmol/mol) ( (Table 3 ). Although significant, the predictive power of diabetes duration and baseline 2-h SMPG was less ( Table 3 ). Sex and hypoglycaemia during the study were consistent with the findings used with categorical cut-offs.
| DISCUSSION
Recognition of the characteristics that influence treatment outcomes will enable clinicians to develop more efficient treatment strategies with an end-of-treatment HbA1c of >8.0% (>64 mmol/mol).
We also observed that an increase in body weight over 24 weeks was modestly associated with failure to attain a good HbA1c response and was consistent with the premise that lifestyle modification, especially in conjunction with commencing basal insulin, is important in achieving glucose targets. Unexpectedly, higher baseline body weight or a higher BMI were modest and independent predictors of achieving a better response. 6, 10 In addition, the poor-responder group received more insulin as a consequence of greater dose titration, but had fewer hypoglycaemia events, suggesting the possibility of more insulin resistance.
Although the final insulin dose when weight adjusted was clearly different between the HbA1c responder groups, this could be related, in part, to the differences in body weight rather than dose. The final insulin dose was not retained as an explanatory variable in the multivariable analyses, suggesting that it was closely associated with another strong predictor that could only be baseline HbA1c.
Hypoglycaemia was a modestly powerful explanatory factor, with a higher incidence associated with attainment of target levels in accordance with other reports, [14] [15] [16] with the exception of the ACCORD study. 17 In our study population, hypoglycaemia occurrence was not a barrier to better control, even though, in short-term, treat-to-target studies, the overall incidence is high. Within each responder group, a higher event rate was associated with lower insulin dose and lower baseline C-peptide levels, as reported by others, suggesting the existence of sub-populations with greater insulin deficiency and higher insulin sensitivity. 2, 18, 19 Overall, the contribution of diabetes duration to predicting the achievement of glycaemic outcome is lower than that of HbA1c. This could be a consequence of the burden of disease, as those using two OADs during the study achieved less benefit overall, consistent with previous observations. 6,10-12 In addition, those using sulfonylureas during the study were less successful in achieving the HbA1c target, independently of other factors, such as hypoglycaemia and weight gain, with the odds changing only marginally between univariable and multivar- In the present study, individuals with higher HbA1c levels at 24 weeks recorded higher 2-h SMPG values, both at baseline and at endpoint, for each meal. The absolute reduction in PPG between baseline and 24 weeks appears to be greatest with breakfast and least with dinner, possibly reflecting the waning biological activity of Gla-100 toward the end of the 24-hour period. Interestingly, change in FPG and, to a lesser extent, the 2-h SMPG was only slightly greater in the good-than in the sub-optimal-or minimal-responder groups;
although this was proportionately less in the latter group because baseline levels were much higher.
Female sex was a modest predictor of difficulty in attaining the HbA1c target on basal insulin, an association that survived into the multivariable models and is consistent with previous reports. 6, 9, 10, 20 A limitation of this study is the focus on HbA1c goal attainment rather than using HbA1c as a continuous variable that might have identified additional factors important for improving glucose control rather than goal achievement.
While findings of the present analysis are consistent with those of other RCTs, pharmaco-epidemiological and prospective cohort studies involving basal insulin and other insulin types, 6, 8, [10] [11] [12] 20, 21 the analysis reflects only a subpopulation of those starting insulin in the real world. 6 This study focused on whether patients with poorly controlled T2DM while using an OAD can achieve the recommended HbA1c goal of <7.0% with the introduction of basal insulin Gla-100. This pooled analysis of individuals with T2DM with a mean HbA1c of 8.7%
(72 mmol/mol) at baseline demonstrated that 54% of the study population did not achieve an HbA1c level of <7.0% (<53 mmol/mol) following the addition of basal insulin.
The results further suggest that, in individuals with a higher baseline HbA1c (>8.0%; >64 mmol/mol), basal insulin supplementation may need to be more aggressive, while also considering the risk of hypoglycaemia. Therefore, when an adequate response is not achieved, consideration should be given to other therapies to address excessive PPG excursions, such as prandial insulin, sodium glucose cotransporter 2 inhibitors or a GLP-1 RA in a free or fixed combination with insulin. Early introduction of basal insulin in combination with a GLP-1 RA may be an option for individuals with T2DM with persistently poor glycaemic control despite the use of multiple OADs. 22 
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